. Ivacaftor globally changes the SCV relationships in the phenotype landscape. Related to Figure 3. (A) The spatial relationships of all possible variant pairwise combinations (64 variants; 2,016 comparisons) (Van Goor et al., 2014; Yu et al., 2012) representing the spatial variance of ClCon and the distance value defined by VarSeqP and TrIdx in the absence (black circles) or presence of Ivacaftor (red circles) are plotted. A comparison of all spatial variance of ClCon in the absence or presence of Ivacaftor is shown in the right inset as a box display. Student's two-tailed t-test p-value is indicated. (B) The averaged spatial variance (mean ± SEM) for each distance bin of 0.01 used to define the distance molecular range (spatially correlated features) and plateau value (spatially uncorrelated variance) is shown in the absence (black, range = ~0.14, plateau = 0.05) or presence of Ivacaftor (red, range = ~0.15, plateau = 0.29). The increase observed in the plateau value in response to Ivacaftor, while maintaining a similar molecular range, reflects that the average diversity of ClCon function is increased by Ivacaftor while the TrIdx values of variants are not changed. , 2017) . VSP predicts that TM8 near the outer pore region also does not respond to Ivacaftor indicating the conformational change of TM8 upon phosphorylation and ATP-binding (Zhang et al., 2017) is critical for the biochemical interaction with Cl -. The response of S977F in ICH3-TM9 to Ivacaftor in the channel gating region is also minor (yellow in Ivacaftor condition), reflecting the fact that it is a critical residue mediating association and disassociation with the regulatory R domain conferring gating properties to the channel. Although G970R has been shown to be responsive to Ivacaftor in cell-based assays, its proximity to a Ivacaftor resistant SCV cluster contributed by S977F ( Figure 3A , right panel) indicates that the functional SCV relationships of G970R may lead to resistance to Ivacaftor, which is indeed found to be the case in clinical trials (De Boeck et al., 2014) . These results emphasize that VSP phenotype landscapes, generated on the basis of variation across the diverse CF population, can inform on risk management and clinical interventional strategies that are pertinent to the individual. Figure 3A . For example, F508 (A) represents a 2D slice (Inset, gray plane) from the 3D view ( Figure S2C ) showing both the basal-and Ivacaftor responsive ClCon ( Figure 3A) . The indicated value of the x-axis (A-C) is the measured or predicted Trldx value shown on the y-axis in Figure 3A . The indicated y-axis in the 2D plot (A-C) shows the measured or predicted ClCon value shown on the z-axis value in Figure 3A . The cell-based measurement of TrIdx and ClCon value for F508del (A), G551S/G551D (B) or S549R/S549N (C) are indicated by the vertical lines. Such a plot reveals all possible measured and predicted TrIdx and ClCon generated by the VSP analysis for each sequence position. The 2D slice illustrates that the range of SCV relationships could be impacted by modifiers, the chemical properties of a variant amino acid residue at the same position, and/or a therapeutic. For example, homozygous F508del/F508del can be differentially responsive to Ivacaftor if an individual has unknown genetic modifier or has encountered a more favorable environment that supports an altered level of trafficking (A, increased y-axis value of red line). This prediction is validated by a drug therapy that combines Lumacaftor/Tezacaftor (ER export correctors) together with Ivacaftor (Orkambi) that modestly improves F508del variant response in the clinic (Taylor-Cousar et al., 2017; Wainwright et al., 2015) (A, region indicated by *). Any further improvement of trafficking (A, region indicated by **) is predicted to have a high impact on channel function leading to increased ClCon and clinical impact (https://cysticfibrosisnewstoday.com/2018/02/22/vertex-begins-cf-phase-3-trial-triplecombo-vx-659-tezacaftor-kalydeco/). In contrast, G551D, normally very responsive to Ivacaftor given that it is found on the cell surface (B, region indicated by **) would become less responsive to Ivacaftor if a modifier decreases its normal efficient trafficking to the cell surface and/or its steady-state value at the surface reflecting internalization through the endosomal/lysosomal pathways (B, region indicated by *). Furthermore, different variants can be found in the same position, such as S549R and S549N (C). They have different trafficking values and thus have different responses to Ivacaftor, which is recorded in the 2D slice and predicted by VSP (see leave-one-out prediction highlighted by red arrows in Figure S2F , Figure S2I ). Figure 3A) . In support of the predictions, the clinical trial response to Ivacaftor of patients with the A455E variant have a higher SC value (lower function) following Ivacaftor treatment indicating an adverse effect of the drug on these patients (McGarry et al., 2017) . The ability to convert single metric responses of cell-based assays (e.g., ClCon) to a therapeutic to multi-dimensional SCV relationships using variation measured or predicted for the entire CF population highlights the power of VSP to enable a genomics-based predictive risk management assessment for treatment of each individual in the CF community as high definition medicine approach (Torkamani et al., 2017) . Figure S4. Delta phenotype landscapes showing variants that report on a specific clinical phenotype. Related to  Figure 4 . The delta contrast maps between bench and bedside phenotype landscapes ( Figure 4A ) for all features are plotted. Dark red and blue regions show significant differences between phenotype landscapes for a ∆ value > 0.25 when setting F508del as '0' and WT as '1'. (A) Contrast maps report on the similarity or difference of a clinical feature from the cell-based ClCon measurement when using TrIdx as the common y-axis coordinate. Such ∆ phenotype landscapes reveal that some variants either under-(circle 5), or over-(circle 6) estimate the potential impact of a variant on a given clinical phenotype relative to the cell-based derived metric ( Figure 4B ). Moreover, ∆ clusters 7-9 illustrate that SCV predicts the unique roles a given variant can have in a specific tissue environment ( Figure 4B ). (B) Contrast maps between SC and other cell-based and clinical features (z-axis predictions). Highlighted by black arrows are the regions that consistently show significant differences between the SC feature and ClCon, FEV1 and PB features. For example, the red region contributed by S997F and L997F indicates that this region has a 'healthier' SC phenotype (WT-like SC) than found for ClCon, FEV1 and PB phenotypes (a more F508del-like value). These results indicate a potential role for tissue-specific modifiers that alter the sequence-to-function-to-structure relationships of this SCV cluster to optimize the SC phenotype. (C) Contrast maps between FEV1 and other features (z-axis predictions). The regions that consistently show significant difference in all panels are highlighted by black arrows. For example, E92K, V754M, D614G and S1251N are consistently associated with a more severe FEV1 clinical phenotype than observed for other clinical phenotypes, implying that these variants may affect specific pathway(s) impacting FEV1 in lung tissue. In contrast, the regions contributed by R74W, P205S and L227R consistently show a better FEV1 phenotype where compared to other phenotypes, indicating the activity of a variant-specific modifier of FEV1 relative to other clinical phenotypes. (D) Contrast maps between PB and other features (z-axis predictions). P205S (black arrow) shows a more severe PB value than other clinical phenotypes (SC, FEV1 and PI) . V754M has diverse phenotype responses as indicated by black arrows in different tissue environments. (E) Contrast maps between PI and other features (z-axis predictions). Large areas of deep red in each contrast map indicate that the PI phenotype landscape is distinct from other phenotype landscapes. Among them, R334W and T338I are important for chloride channel activity, and are resistant to Ivacaftor treatment ( Figure S2J, TM6) , indicating that the pancreas may have tissue-specific modifiers of the fold reflecting the community of protein-protein interactions (Pankow et al., 2015) that modify the functional properties of these variants to tailor conductance to pancreatic function. This interpretation is consistent with the observation that many variants that impact bicarbonate permeation and onset of pancreatitis but not CF (e.g., R74W, R75Q, R117H, S1235R, and D1270N) are predicted to be normal in all other CF phenotype landscapes ( Figure  2A ) (LaRusch et al., 2014) . (C) Leave-one-out cross-validation result for Figure 5C. (B) Leave-one-out cross-validation result for Figure 5D .
(E) The molecular variogram of TrIdx landscape in Figure 5C .
(F) The molecular variogram of ClCon landscape in Figure 5D .
(G-H) Compare VSP prediction of TrIdx (G) and ClCon (H) based on allele frequency to other variant prediction methods. F508del and I507del are removed for the comparison given most of other methods can only predict the impact of missense variants. As shown in (G), VSP generates a significantly more accurate prediction of TrIdx than other variant predictive methods including Polyphen-2, SIFT, CADD, M-CAP, Envision (Gray et al., 2018) , Grantham, as well as POSE (Masica et al., 2015) that was trained with the same TrIdx dataset. This result indicates that VSP uniquely captures the local SCV relationships defined by allele frequency ( Figure 5C ; Figure S5E ) that drives trafficking by highly regionalized properties of the fold (e.g., NBD1 and TMD2 in Figure 2C ) to regulate export from the ER. On the other hand, VSP achieves slightly higher accuracy in predicting ClCon function when compared with other methods based on ancestral sequence alignment (e.g. SIFT, Polyphen-2, POSE etc.), indicating that ClCon function represents the evolutionary trajectory of the fold consistent with the broad range in correlating with allele frequency in the SCV relationships for the entire CFTR polypeptide ( Figure 5D ; Figure S5F ).
